← Back to patent-cliff list
BHB-1893
Tier C — Watch / tradeBHB-1893
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Cardiac myosin
Indications (approved)：Hypertrophic cardiomyopathy, Cardiomyopathy, Diastolic heart failure, Heart failure
Regional status
US
-
EU
-
China
Phase III
2025-08-11
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BHB-1893?
Approved indications include: Hypertrophic cardiomyopathy, Cardiomyopathy, Diastolic heart failure, Heart failure.
When does the BHB-1893 patent expire?
No public expiry year is available for BHB-1893 yet; this page updates once verified.
How do I get a quote for BHB-1893 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30